Research established a licensing agreement for the use of Biosystems International
’s (BSI) mAb proteomics
platform. Lohocla will utilize the technology for the discovery of alcoholic liver disease biomarkers
in the blood.
BSI reports that it uses a hypothesis-free process to perform mAb-based comparative and quasi-global plasma proteome profiling. This allows the detection of potential biomarker candidates with no preconceived bias, the firm states. As a result, the BSI discovery process claims to provide tools for quantitative biomarker assays in clinical trials, which is something the company says current proteomics-based approaches do not deliver.